000 | 01954 a2200565 4500 | ||
---|---|---|---|
005 | 20250515000131.0 | ||
264 | 0 | _c20051220 | |
008 | 200512s 0 0 eng d | ||
022 | _a0300-483X | ||
024 | 7 |
_a10.1016/j.tox.2005.07.012 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aManiratanachote, Rawiwan | |
245 | 0 | 0 |
_aDetection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. _h[electronic resource] |
260 |
_bToxicology _cDec 2005 |
||
300 |
_a15-23 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAlanine Transaminase _xblood |
650 | 0 | 4 |
_aAutoantibodies _xblood |
650 | 0 | 4 |
_aChemical and Drug Induced Liver Injury _xblood |
650 | 0 | 4 |
_aChromans _xadverse effects |
650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
650 | 0 | 4 | _aElectrophoresis, Gel, Two-Dimensional |
650 | 0 | 4 | _aElectrophoresis, Polyacrylamide Gel |
650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFructose-Bisphosphate Aldolase _ximmunology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
650 | 0 | 4 | _aImmunoblotting |
650 | 0 | 4 |
_aLiver _xdrug effects |
650 | 0 | 4 |
_aLiver Cirrhosis _xblood |
650 | 0 | 4 |
_aLiver Diseases _xblood |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aSubcellular Fractions _xdrug effects |
650 | 0 | 4 |
_aThiazolidinediones _xadverse effects |
650 | 0 | 4 | _aTroglitazone |
700 | 1 | _aShibata, Ayaka | |
700 | 1 | _aKaneko, Shuichi | |
700 | 1 | _aYamamori, Ikuo | |
700 | 1 | _aWakasugi, Takanobu | |
700 | 1 | _aSawazaki, Takeshi | |
700 | 1 | _aKatoh, Kanefusa | |
700 | 1 | _aTokudome, Shogo | |
700 | 1 | _aNakajima, Miki | |
700 | 1 | _aYokoi, Tsuyoshi | |
773 | 0 |
_tToxicology _gvol. 216 _gno. 1 _gp. 15-23 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.tox.2005.07.012 _zAvailable from publisher's website |
999 |
_c15752644 _d15752644 |